SAN DIEGO, December 29, 2021 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (GMO) solutions on the Saphyr® system and provider of leading software solutions for visualization, interpretation and communication of genomic data, today announced that it has completed the first prototype of its upcoming single-molecule imaging system for GMOs. The prototype is used to integrate and test key engineering designs for a new instrument and consumable designed to meet the needs of high volume users. The trading system based on this prototype is expected to be released in the first half of 2023.
We believe that GMO provides the most complete, reliable and cost effective solution for detecting structural variations (SV). GMO is a workflow consisting of four exclusive steps: (i) isolation of ultra-high molecular weight DNA; (ii) DNA sequence specific labeling; (iii) linearization and imaging of a single molecule; and (iv) data processing and analysis. The third step creates the images of molecules and the patterns of sequence motifs which are used to reveal the SVs. This step also sets the limit on the number of samples that can be processed per day. The current Saphyr system’s throughput is designed for volumes encountered by academic medical centers performing standard clinical genomics research, but large reference laboratories and contract research organizations (CROs) with higher volumes require an instrument with higher flow capacities.
Compared to the Saphyr system, which images DNA at a rate of around 205 Gbp per hour, the new system is expected to image close to 820 Gbp per hour. The new instrument is designed to be configurable as a set of up to four instruments processing samples in parallel approximately six months after initial release. Other expected features of the new system include a new consumable design, a larger capacity carousel for staging samples to be imaged, and updated optical components, all in a small footprint benchtop footprint.
The new imaging system will also incorporate features designed to make high-throughput workflows more flexible, allowing data collection to begin without the need to wait for multiple samples to become available, allowing experiments to be run on the high coverage cancer alongside lower coverage constitutional experiments and the ability to prioritize which samples to run before all others. This flexibility is expected to exceed that of peer-to-peer sequencing systems, where achieving this flexibility often means waiting for enough samples to fill a flow cell or paying a hefty premium per sample for one sample to consume more consumable.
Erik Holmlin, PhD, President and CEO of Bionano said: “I want to congratulate our team for completing this prototype on time. With the planned integration of GMOs into NxClinical in 2022, the leading software solution for visualization, interpretation and reporting of single nucleotide variants and copy number variants from sequencing and DNA microarrays generation, we believe this new system and consumable will be the next major additions to our product list for the growing community of GMO users. I am impressed by the innovation that our team brought to the project and I look forward to their development in 2022. ”
Mark Oldakowski, COO of Bionano said: “Guided by our intimate knowledge of our customers’ needs, the progress made by this team has been spectacular. Next year, I look forward to sharing more incredible advancements for this new imaging system which we hope will delight our customers.
Prototype photos of the upcoming single-molecule imaging system for GMOs will be available on Bionano’s social media on December 31, 2021.
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to difficult questions in biology and medicine. The company’s mission is to transform the way the world views the genome through GMO solutions, diagnostic services and software. The Company offers GMO solutions for applications in basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic tests for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the Company also offers an industry-leading, platform-independent software solution that integrates next-generation DNA sequencing and microarray data designed to provide analysis, visualization, interpretation and analysis. ratio of copy number variants, single nucleotide variants and absence. of heterozygosity across the genome in a consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com.
Bionano Genomics forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “plan”, “anticipate”, “estimate” , “Intend to” and similar expressions (as well as other words or phrases referring to future events, conditions or circumstances) convey the uncertainty of future events or results and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analysis or current expectations regarding, among other things, [timing for anticipated launch of the commercial system;] [whether Saphyr will remain available for purchase after the new system is released;] the anticipated performance of the new system and its anticipated characteristics, as well as the anticipated performance of the new system relative to competing sequencing systems; and the timing of progress in the new system. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products, technologies or improvements in existing technologies; a reduction in large reference laboratories and CROs seeking to integrate GMOs internally; delays in advancing and developing the prototype into a commercially available system; changes in our strategic and business plans; our ability to secure sufficient funding to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2020 and in other documents subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of that date. We assume no obligation to publicly update any forward-looking statements, whether as a result of receipt of new information, the occurrence of future events, or otherwise.
Company details :
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
+1 (858) 366-3243
+1 (503) 799-7520